BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 34475199)

  • 1. Excessive Laughter-like Vocalizations, Microcephaly, and Translational Outcomes in the
    Berg EL; Jami SA; Petkova SP; Berz A; Fenton TA; Lerch JP; Segal DJ; Gray JA; Ellegood J; Wöhr M; Silverman JL
    J Neurosci; 2021 Oct; 41(42):8801-8814. PubMed ID: 34475199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Translational outcomes in a full gene deletion of ubiquitin protein ligase E3A rat model of Angelman syndrome.
    Berg EL; Pride MC; Petkova SP; Lee RD; Copping NA; Shen Y; Adhikari A; Fenton TA; Pedersen LR; Noakes LS; Nieman BJ; Lerch JP; Harris S; Born HA; Peters MM; Deng P; Cameron DL; Fink KD; Beitnere U; O'Geen H; Anderson AE; Dindot SV; Nash KR; Weeber EJ; Wöhr M; Ellegood J; Segal DJ; Silverman JL
    Transl Psychiatry; 2020 Jan; 10(1):39. PubMed ID: 32066685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypersociability in the Angelman syndrome mouse model.
    Stoppel DC; Anderson MP
    Exp Neurol; 2017 Jul; 293():137-143. PubMed ID: 28411125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered ultrasonic vocalization and impaired learning and memory in Angelman syndrome mouse model with a large maternal deletion from Ube3a to Gabrb3.
    Jiang YH; Pan Y; Zhu L; Landa L; Yoo J; Spencer C; Lorenzo I; Brilliant M; Noebels J; Beaudet AL
    PLoS One; 2010 Aug; 5(8):e12278. PubMed ID: 20808828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of a Novel Rat Model of Angelman Syndrome with a Complete Ube3a Gene Deletion.
    Dodge A; Peters MM; Greene HE; Dietrick C; Botelho R; Chung D; Willman J; Nenninger AW; Ciarlone S; Kamath SG; Houdek P; Sumová A; Anderson AE; Dindot SV; Berg EL; O'Geen H; Segal DJ; Silverman JL; Weeber EJ; Nash KR
    Autism Res; 2020 Mar; 13(3):397-409. PubMed ID: 31961493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin-like growth factor-2 does not improve behavioral deficits in mouse and rat models of Angelman Syndrome.
    Berg EL; Petkova SP; Born HA; Adhikari A; Anderson AE; Silverman JL
    Mol Autism; 2021 Sep; 12(1):59. PubMed ID: 34526125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abnormal electrophysiological phenotypes and sleep deficits in a mouse model of Angelman Syndrome.
    Copping NA; Silverman JL
    Mol Autism; 2021 Feb; 12(1):9. PubMed ID: 33549123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Normal social seeking behavior, hypoactivity and reduced exploratory range in a mouse model of Angelman syndrome.
    Allensworth M; Saha A; Reiter LT; Heck DH
    BMC Genet; 2011 Jan; 12():7. PubMed ID: 21235769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced Operant Extinction and Prefrontal Excitability in a Mouse Model of Angelman Syndrome.
    Sidorov MS; Judson MC; Kim H; Rougie M; Ferrer AI; Nikolova VD; Riddick NV; Moy SS; Philpot BD
    J Neurosci; 2018 Mar; 38(11):2671-2682. PubMed ID: 29431654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A behavioral test battery for mouse models of Angelman syndrome: a powerful tool for testing drugs and novel
    Sonzogni M; Wallaard I; Santos SS; Kingma J; du Mee D; van Woerden GM; Elgersma Y
    Mol Autism; 2018; 9():47. PubMed ID: 30220990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angelman syndrome - insights into a rare neurogenetic disorder.
    Buiting K; Williams C; Horsthemke B
    Nat Rev Neurol; 2016 Oct; 12(10):584-93. PubMed ID: 27615419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Seizure-like activity in a juvenile Angelman syndrome mouse model is attenuated by reducing Arc expression.
    Mandel-Brehm C; Salogiannis J; Dhamne SC; Rotenberg A; Greenberg ME
    Proc Natl Acad Sci U S A; 2015 Apr; 112(16):5129-34. PubMed ID: 25848016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Communication-related assessments in an Angelman syndrome mouse model.
    Perrino PA; Chamberlain SJ; Eigsti IM; Fitch RH
    Brain Behav; 2021 Jan; 11(1):e01937. PubMed ID: 33151040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased Axon Caliber Underlies Loss of Fiber Tract Integrity, Disproportional Reductions in White Matter Volume, and Microcephaly in Angelman Syndrome Model Mice.
    Judson MC; Burette AC; Thaxton CL; Pribisko AL; Shen MD; Rumple AM; Del Cid WA; Paniagua B; Styner M; Weinberg RJ; Philpot BD
    J Neurosci; 2017 Aug; 37(31):7347-7361. PubMed ID: 28663201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recovery of Angelman syndrome rat deficits with UBE3A protein supplementation.
    Dodge A; Morrill NK; Weeber EJ; Nash KR
    Mol Cell Neurosci; 2022 May; 120():103724. PubMed ID: 35367589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angelman syndrome protein UBE3A interacts with primary microcephaly protein ASPM, localizes to centrosomes and regulates chromosome segregation.
    Singhmar P; Kumar A
    PLoS One; 2011; 6(5):e20397. PubMed ID: 21633703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Behavioral Evaluation of Angelman Syndrome Mice at Older Ages.
    Dutta R; Crawley JN
    Neuroscience; 2020 Oct; 445():163-171. PubMed ID: 31730795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of UBE3A Protein in CSF and Extracellular Space of the Hippocampus Suggest a Potential Novel Function in Synaptic Plasticity.
    Dodge A; Willman J; Willman M; Nenninger AW; Morrill NK; Lamens K; Greene H; Weeber EJ; Nash KR
    Autism Res; 2021 Apr; 14(4):645-655. PubMed ID: 33474832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adult
    Rotaru DC; van Woerden GM; Wallaard I; Elgersma Y
    J Neurosci; 2018 Sep; 38(37):8011-8030. PubMed ID: 30082419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation and Characterization of a Novel Angelman Syndrome Mouse Model with a Full Deletion of the
    Syding LA; Kubik-Zahorodna A; Nickl P; Novosadova V; Kopkanova J; Kasparek P; Prochazka J; Sedlacek R
    Cells; 2022 Sep; 11(18):. PubMed ID: 36139390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.